TY - JOUR T1 - Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 955 LP - 962 DO - 10.1136/ijgc-00009577-200605000-00001 VL - 16 IS - 3 AU - A. Longatto-Filho AU - M. Eržen AU - M. Branca AU - C. Roteli-Martins AU - P. Naud AU - S. F.M. Derchain AU - L. Hammes AU - L. O. Sarian AU - J. F. Bragança AU - J. Matos AU - R. Gontijo AU - T. Lima AU - M. Y.S. Maeda AU - S. Tatti AU - S. Syrjänen AU - G. Dores AU - A. LÖRINCZ AU - K. Syrjänen Y1 - 2006/04/01 UR - http://ijgc.bmj.com/content/16/3/955.abstract N2 - Hybrid capture II (HC II) test for oncogenic human papillomaviruses (HPV) was carried out in a cohort of 4284 women at their first clinical visit. Overall prevalence of HPV was 17.1%, decreasing with age from 33.9% among women below 20 years to only 11.0% among those older than 41 years. HPV prevalence was significantly higher among current smokers (odds ratio [OR] = 1.31; 95% CI 1.1–1.6), in women with two or more lifetime sexual partners (OR = 1.9; 95% CI 1.6–2.4), and those women with two or more sexual partners during the past 12 months prior to examination (OR = 1.6; 95% CI 1.2–2.2). HPV detection increased in parallel with increasing cytologic abnormality, being highest in women with high-grade squamous intraepithelial lesion (P = 0.001). Specificity of the HPV test in detecting histologically confirmed cervical disease was 85% (95% CI 83.9–86.1). Sensitivity of the HPV test in detecting histologic abnormalities increased in parallel with disease severity, ranging from 51.5% for cervical intraepithelial neoplasia (CIN) 1 to 96.5% for CIN 3 and 100.0% for cancer, with respective decline of positive predictive value. These data suggest that HPV testing with HC II assay might be a viable screening tool among this population with relatively high prevalence of cervical disease. ER -